Valuation: Patrys Limited

Market Cap 23.33M 16.65M 14.42M 13.61M 12.35M 23.16M 1.6B 163M 62.64M 809M 62.52M 61.14M 2.57B P/E 2024
-4.06x
P/E 2025 -0.68x
Enterprise Value 22.59M 16.12M 13.96M 13.18M 11.96M 22.43M 1.54B 157M 60.65M 784M 60.53M 59.19M 2.49B EV / Sales 2024
8.72x
EV / Sales 2025 1.96x
Free-Float
70.71%
Yield 2024 *
-
Yield 2025 -
1 day+2.94%
1 week+9.38%
Current month+16.67%
1 month+9.38%
3 months-28.57%
6 months+16.67%
Current year+25.00%
1 week 0.03
Extreme 0.031
0.04
1 month 0.03
Extreme 0.03
0.04
Current year 0.02
Extreme 0.025
0.05
1 year 0.01
Extreme 0.014999
0.05
3 years 0.01
Extreme 0.011987
0.13
5 years 0.01
Extreme 0.011987
0.56
10 years 0.01
Extreme 0.011987
0.91
Manager TitleAgeSince
Chief Executive Officer - 2026-02-15
Chief Operating Officer - 2012-05-31
Corporate Secretary - 2025-11-09
Director TitleAgeSince
Director/Board Member - 2025-06-16
Chairman 64 -
Director/Board Member - 2025-11-09
Date Insider Type Main position Quantity % Market Cap. Importance
8/11/23 Expiration

Chief Executive Officer

396,132 0.0193%
8/11/23 Expiration

Chief Executive Officer

3,283 0.0002%
12/6/21 Buy

Chief Executive Officer

1,337,164 0.0675%
Change 5-day change 1-year change 3-year change Capi.($)
+2.94%+9.38%+16.67%-58.33% 16.17M
+5.04%+3.66%+50.62%+103.77% 70.24B
-0.39%-0.16%+35.49%+76.30% 62.63B
-3.18%-0.78%-14.14%+369.82% 27.36B
+0.16%-0.16%+26.73%+12.12% 25.71B
+2.20%-4.72%+2.19%-13.14% 24.83B
-0.99%-3.14%+17.88%-21.40% 19.52B
-7.03%-10.19%+161.91%+303.00% 15.51B
-3.91%-5.25%-9.16%+485.32% 14.66B
+4.96%+4.63%-2.75%+864.40% 14.69B
Average -1.09%-0.31%+28.54%+212.19% 27.52B
Weighted average by Cap. -0.04%-0.80%+32.05%+168.15%

Financials

2024 2025
Net sales 1.39M 995K 862K 813K 738K 1.38M 95.33M 9.71M 3.74M 48.36M 3.74M 3.65M 154M 829K 591K 512K 483K 438K 823K 56.65M 5.77M 2.22M 28.74M 2.22M 2.17M 91.37M
Net income -3.54M -2.52M -2.19M -2.06M -1.87M -3.51M -242M -24.66M -9.5M -123M -9.48M -9.27M -390M -3.01M -2.15M -1.86M -1.76M -1.59M -2.99M -206M -20.99M -8.09M -105M -8.07M -7.9M -332M
Net Debt -2.24M -1.6M -1.39M -1.31M -1.19M -2.22M -153M -15.61M -6.02M -77.72M -6M -5.87M -247M -742K -530K -459K -433K -393K -737K -50.77M -5.17M -1.99M -25.75M -1.99M -1.95M -81.88M
Logo Patrys Limited
Patrys Limited is an Australia-based company. The Company is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different indications. The Company’s deoxymab platform is based on the deoxymab 3E10 antibody that is identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus (SLE). It has developed two humanized forms of deoxymab 3E10, called PAT-DX1 and PAT-DX3, which have improved activity over the original 3E10 antibody. PAT-DX1 is a dimer of a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10. PAT-DX3 is a humanized, full-sized antibody that has been further optimized to improve its therapeutic potential. It is also focused on developing RLS-2201, a proprietary injectable formulation of quetiapine.
Employees
10
Date Price Change Volume
26-09-15 A$0.0350 +2.94% 2,077,129
26-09-14 A$0.0340 +9.68% 1,332,686
26-09-11 A$0.0310 -3.13% 137,360
26-09-10 A$0.0320 0.00% 493,958
26-09-09 A$0.0320 0.00% 753,479
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!